Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for prevention of contrast-induced nephropathy after coronary angiography or PCI
IRCT20230110057096N1Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of nicorandil in contrast-induced nephropathy (CIN) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Creatinine level, BUN level and 1 more. Started Feb 2023; status: completed.
02
Drugs
nicorandil
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20230110057096N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230110057096N1.